Mergers & Acquisitions

Boston Scientific acquires EndoTex Interventional Systems

Published in Biotech Business Week, January 29th, 2007

Boston Scientific Corp. (BSX) announced it has acquired EndoTex Interventional Systems, Inc. The acquisition follows the Food and Drug Administration (FDA) approval of the NexStent Carotid Stent System, which was studied in the CABERNET trial along with the Boston Scientific FilterWire EZ Embolic Protection System.

Terms of the acquisition were not disclosed.

"Combining the resources of these two organizations demonstrates Boston Scientific's commitment to leadership in treating carotid artery disease," said John Pedersen, president of Boston Scientific's Peripheral Interventions business. "Incorporating the NexStent Carotid Stent into our portfolio...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Biotech Business Week

Source: Biotech Business Week (2007-01-29)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry